NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
August 19, 2008 • Volume 5 / Number 17 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Director's Update

The Dawn of Personalized Oncology

Wherever I go, someone invariably asks, "Have we really made any progress against cancer?" My answer is, We definitely have - we have made tremendous progress.

I go on to explain how much more we know today than we did just a decade or two ago. We know that the tumor has a very significant and critical microenvironment in which it grows; that the normal-appearing cells of this microenvironment are genetically reprogrammed to support the growing tumor in the critical steps of invasion and metastasis. We know much more about mutations, changes in gene copy number, translocations, the re-expression of genes involved in embryogenesis, and the epigenetic suppression of other genes - and how these changes lead to the growth and spread of cancer.

This new knowledge is being determined and catalogued at a stunning rate, led by our research efforts in functional biology and by our work in genomics and transcriptional regulation. In addition, whole-genome scans that define regions associated with cancer risk are being identified, fine mapped, and sequenced. The Cancer Genome Atlas (TCGA) project is actively sequencing actual patient tumors and finding new gene alterations associated with a specific cancer's development.  Read more  


Mobilizing National Drug Discovery

NCI's proposed Chemical Biology Consortium (CBC) will establish an integrated network of chemical biologists, molecular oncologists, and compound screening centers from government, academia, and eventually from industry. The program is being developed by NCI's Division of Cancer Treatment and Diagnosis (DCTD), in conjunction with NCI's Center for Cancer Research (CCR) and the NCI Director's office, to facilitate the discovery and development of new agents to treat cancer.

"The long-term vision of the CBC is to bridge the gap between basic scientific findings - for example, The Cancer Genome Atlas and genome-wide association studies - and NCI-supported clinical research," noted DCTD Director Dr. James Doroshow.

Dr. Barbara Mroczkowski, special assistant to the DCTD director, is a project lead for CBC. She came to NCI after 15 years in industry.  Read more  



The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.